[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100221602":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":21,"centralContacts":10,"locations":26,"responsibleParty":31,"collaborators":10,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":10,"acronym":10,"eligibilityCriteria":38,"healthyVolunteers":35,"sex":39,"minAge":10,"maxAge":10,"enrollmentInfo":40,"targetDuration":10,"studyType":43,"phases":10,"briefSummary":44,"conditions":45,"keywords":47,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":59},{"fullName":5,"class":6},"Eisai Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"E2020",null,[12],"Drug: Donepezil Hydrochloride",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Donepezil Hydrochloride","Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.",[9],[20],"Aricept",[22],{"name":23,"affiliation":24,"role":25},"Kazuhiro Omata","Drug Fostering and Evolution Coordination Department, Eisai Co., Ltd.","STUDY_DIRECTOR",[27],{"facility":10,"status":10,"city":28,"state":10,"zip":10,"country":29,"countryCode":30,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Multiple Locations","Japan","JP",{"type":32,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100221602","post-marketing-surveillance-of-donepezil-hydrochloride--investigation-of-the-factors-that-affect-aricept-medication-persistence-rate-and-the-safety-and-efficacy-in-patients-with-alzheimers-disease-in-clinical-practice-100221602",false,"NCT02162264","Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice","Inclusion criteria:\n\nPatients diagnosed with Alzheimer's Disease and administered Aricept for the first time.\n\nExclusion criteria:\n\nPatients with a history of hypersensitivity to any ingredients of Aricept or piperidine derivatives.","ALL",{"count":41,"type":42},8662,"ACTUAL","OBSERVATIONAL","To investigate the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice",[46],"Alzheimer's Disease",[46,48],"donepezil hydrochloride","COMPLETED","2018-09-06",{"date":52,"type":42},"2018-09-07",{"date":54,"type":42},"2013-06-01",{"date":56,"type":42},"2016-07-22",{"name":58,"class":6},"Eisai Co., Ltd.",1]